Terms: = Bone cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
270 results:
1. Altered erythropoiesis via jak2 and ASXL1 mutations in myeloproliferative neoplasms.
Collins TB; Laranjeira ABA; Kong T; Fulbright MC; Fisher DAC; Sturgeon CM; Batista LFZ; Oh ST
Exp Hematol; 2024 Apr; 132():104178. PubMed ID: 38340948
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Morsia E; Torre E; Martini F; Morè S; Poloni A; Olivieri A; Rupoli S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338802
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.
Del Dosso A; Tadevosyan E; Berenson JR
Oncotarget; 2024 Feb; 15():65-75. PubMed ID: 38319731
[TBL] [Abstract] [Full Text] [Related]
4. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
5. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
6. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Palandri F; Palumbo GA; Benevolo G; Iurlo A; Elli EM; Abruzzese E; Polverelli N; Tiribelli M; Auteri G; Tieghi A; Caocci G; Binotto G; Cavazzini F; Branzanti F; Beggiato E; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Scaffidi L; Venturi M; Duminuco A; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Trawinska MM; Vianelli N; Cavo M; Bonifacio M; Breccia M
Cancer; 2024 Apr; 130(8):1270-1280. PubMed ID: 38153814
[TBL] [Abstract] [Full Text] [Related]
7. A newly identified 45-kDa jak2 variant with an altered kinase domain structure represents a novel mode of jak2 kinase inhibitor resistance.
Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
[TBL] [Abstract] [Full Text] [Related]
8. The highs and lows of cyclic thrombocytopenia.
Zhang H; Villar-Prados A; Bussel JB; Zehnder JL
Br J Haematol; 2024 Jan; 204(1):56-67. PubMed ID: 38083878
[TBL] [Abstract] [Full Text] [Related]
9. High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis.
De Luca G; Lev PR; Camacho MF; Goette NP; Sackmann F; Castro Ríos MA; Moiraghi B; Cortes Guerrieri V; Bendek G; Carricondo E; Enrico A; Vallejo V; Varela A; Khoury M; Gutierrez M; Larripa IB; Marta RF; Glembotsky AC; Heller PG
Front Immunol; 2023; 14():1161832. PubMed ID: 38035089
[TBL] [Abstract] [Full Text] [Related]
10. CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
Al Barashdi MAS; Ali A; McMullin MF; Mills K
Ann Hematol; 2024 Jan; 103(1):73-88. PubMed ID: 37917373
[TBL] [Abstract] [Full Text] [Related]
11. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
Krecak I; Verstovsek S; Lucijanic M
Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349
[TBL] [Abstract] [Full Text] [Related]
12. Detection of primary myelofibrosis in blood serum via Raman spectroscopy assisted by machine learning approaches; correlation with clinical diagnosis.
Guleken Z; Ceylan Z; Aday A; Bayrak AG; Hindilerden İY; Nalçacı M; Jakubczyk P; Jakubczyk D; Kula-Maximenko M; Depciuch J
Nanomedicine; 2023 Sep; 53():102706. PubMed ID: 37633405
[TBL] [Abstract] [Full Text] [Related]
13. Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care.
Chung C
Am J Health Syst Pharm; 2023 Nov; 80(22):1624-1636. PubMed ID: 37556726
[TBL] [Abstract] [Full Text] [Related]
14. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
[TBL] [Abstract] [Full Text] [Related]
15. Next-Generation jak2 Inhibitors for the treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
Nair PC; Piehler J; Tvorogov D; Ross DM; Lopez AF; Gotlib J; Thomas D
Blood Cancer Discov; 2023 Sep; 4(5):352-364. PubMed ID: 37498362
[TBL] [Abstract] [Full Text] [Related]
16. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J; Migliaccio AR; Kosiorek H; Bhave R; Palmer J; Kuykendall A; Mesa R; Rampal RK; Gerds AT; Yacoub A; Pettit K; Talpaz M; Komrokji R; Kremyanskaya M; Gonzalez A; Fabris F; Johnson K; Dougherty M; McGovern E; Arango Ossa J; Domenico D; Farnoud N; Weinberg RS; Kong A; Najfeld V; Vannucchi AM; Arciprete F; Zingariello M; Falchi M; Salama ME; Mead-Harvey C; Dueck A; Varricchio L; Hoffman R
Clin Cancer Res; 2023 Sep; 29(18):3622-3632. PubMed ID: 37439808
[TBL] [Abstract] [Full Text] [Related]
17. Acute graft-versus-host disease.
Malard F; Holler E; Sandmaier BM; Huang H; Mohty M
Nat Rev Dis Primers; 2023 Jun; 9(1):27. PubMed ID: 37291149
[TBL] [Abstract] [Full Text] [Related]
18. The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Wang SA; Orazi A; Gotlib J; Reiter A; Tzankov A; Hasserjian RP; Arber DA; Tefferi A
Am J Hematol; 2023 Aug; 98(8):1286-1306. PubMed ID: 37283522
[TBL] [Abstract] [Full Text] [Related]
19. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/jak2/STAT3 signaling.
Lu J; Dong Q; Zhang S; Feng Y; Yang J; Zhao L
Cancer Sci; 2023 Aug; 114(8):3287-3300. PubMed ID: 37272257
[TBL] [Abstract] [Full Text] [Related]
20. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with jak2
Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
[TBL] [Abstract] [Full Text] [Related]
[Next]